Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β-1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing–Remitting Multiple Sclerosis (TRANSFORMS)

2014 ◽  
Vol 3 (3) ◽  
pp. 355-363 ◽  
Author(s):  
B.O. Khatri ◽  
J. Pelletier ◽  
L. Kappos ◽  
H.-P. Hartung ◽  
G. Comi ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Prior Treatment ◽  
Efficacy And Safety ◽  
Interferon Β ◽  
Treatment Status ◽  
Relapsing Remitting ◽  
Subgroup Analyses ◽  
Remitting Multiple Sclerosis ◽  
Relapsing Remitting Multiple Sclerosis

Efficacy and Safety of Oral Therapies for Relapsing-Remitting Multiple Sclerosis

CNS Drugs ◽  
2020 ◽  
Vol 34 (1) ◽  
pp. 65-92 ◽  
Author(s):  
Damiano Paolicelli ◽  
Alessia Manni ◽  
Antonio Iaffaldano ◽  
Maria Trojano
Keyword(s):  
Multiple Sclerosis ◽  
Efficacy And Safety ◽  
Relapsing Remitting ◽  
Remitting Multiple Sclerosis ◽  
Relapsing Remitting Multiple Sclerosis
Sign in / Sign up

Export Citation Format

Share Document